Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Duck, L.; Bessa, E.; Mueser, M.; Amellal, N.
EJC Suppls 1(5): S34
2003
Accession: 035489535
PDF emailed within 1 workday: $29.90
Related References
Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Humblet, Y.; Lopez-Pousa, A.; Hitt, R.; Vega Villegas, M.E.; Duck, L.; Rosine, D.; Amellal, N.; Schueler, A.; Harstrick, A. 2006: Phase I/Ii study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24(18): 2866-2872Vermorken, J.B.; Mesia, R.; Vega-Villegas, M.E.; Remenar, E.; Hitt, R.; Kawecki, A.; Rottey, S.; Zabolotnyy, D.; Erfan, J.; Amellal, N. 2016: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME) Journal of Clinical Oncology 24(18_Suppl): 5537-5537
Tsakonas, G.; Specht, L.; Kristensen, C.A.; Moreno, M.H.C.; Cange, H.H.; Soderstrom, K.; Friesland, S. 2020: Randomized Phase Ii Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial) Cancers 12(11)
Guo, Y.; Luo, Y.; Zhang, Q.; Huang, X.; Li, Z.; Shen, L.; Feng, J.; Sun, Y.; Yang, K.; Ge, M-H.; Zhu, X.; Wang, L.; Liu, Y.; He, X.; Bai, C.; Xue, K.; Zeng, Y.; Cao, Y.; Chen, W.; Lin, T. 2018: First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 9: Ix176
Cohen, M.H.; Chen, H.; Shord, S.; Fuchs, C.; He, K.; Zhao, H.; Sickafuse, S.; Keegan, P.; Pazdur, R. 2013: Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer Oncologist 18(4): 460-466
Machiels, J.-P.; Kaminsky, M.-C.; Keller, U.; Brümmendorf, T.H.; Goddemeier, T.; Forssmann, U.; Delord, J.-P. 2013: Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck Investigational new Drugs 31(5): 1207-1216
Saba, N.F.; Hurwitz, S.J.; Magliocca, K.; Kim, S.; Owonikoko, T.K.; Harvey, D.; Ramalingam, S.S.; Chen, Z.; Rogerio, J.; Mendel, J.; Kono, S.A.; Lewis, C.; Chen, A.Y.; Higgins, K.; El-Deiry, M.; Wadsworth, T.; Beitler, J.J.; Shin, D.M.; Sun, S.-Y.; Khuri, F.R. 2014: Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck Cancer 120(24): 3940-3951
Vermorken, J.B.; Licitra, L.; Stöhlmacher-Williams, J.; Dietz, A.; Lopez-Picazo, J.M.; Hamid, O.; Hossain, A.M.; Chang, S.-C.; Gauler, T.C. 2013: Phase Ii study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck European Journal of Cancer 49(13): 2877-2883
Vermorken, J.B.; Licitra, L.; Stohlmacherwilliams, J.; Dietz, A.; Lopezpicazo, J.M.; Hamid, O.; Hossain, A.M.; Chang, S.C.; Gauler, T.C. 2013: Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck European Journal of Cancer (1990) 49(13): 2877-2883
Vermorken, J.B.; Peyrade, F.; Brummendorf, T.H.; Iglesias, L.; Bethe, U.; Hicking, C.; Clement, P.M.; Krauss, J.; Mesia, R.; Remenar, E.; Gauler, T.C.; Keilholz, U.; Delord, J.P.; Schafhausen, P.; Erfan, J. 2014: Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase 1/11 ADVANTAGE trial (phase II part) Annals of Oncology 25(3): 682-688
Vermorken, J.B.; Peyrade, F.; Krauss, J.; Mesía, R.; Remenar, E.; Gauler, T.C.; Keilholz, U.; Delord, J.P.; Schafhausen, P.; Erfán, J.; Brümmendorf, T.H.; Iglesias, L.; Bethe, U.; Hicking, C.; Clement, P.M. 2014: Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/Ii ADVANTAGE trial (phase Ii part) Annals of Oncology: Official Journal of the European Society for Medical Oncology 25(3): 682-688
Vermorken, J.B.; Peyrade, F.; Krauss, J.; Mesía, R.; Remenar, E.; Gauler, T.C.; Keilholz, U.; Delord, J.P.; Schafhausen, P.; Erfán, J.; Brümmendorf, T.H.; Iglesias, L.; Bethe, U.; Hicking, C.; Clement, P.M. 2014: Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part) Annals of Oncology: Official Journal of the European Society for Medical Oncology 25(3): 682-688
Guigay, J.ël.; Aupérin, A.; Fayette, J.ér.ôm.; Saada-Bouzid, E.; Lafond, C.éd.; Taberna, M.; Geoffrois, L.; Martin, L.; Capitain, O.; Cupissol, D.; Castanie, H.él.èn.; Vansteene, D.; Schafhausen, P.; Johnson, A.; Even, C.; Sire, C.; Duplomb, S.; Evrard, C.; Delord, J.-P.; Laguerre, B.; Zanetta, S.; Chevassus-Clément, C.éc.; Fraslin, A.ér.; Louat, F.; Sinigaglia, L.; Keilholz, U.; Bourhis, J.; Mesia, R.; Baba-Hamed, N.; Babin, E.; Bera, G.; Betrian-Lagarde, S.; Blot, E.; Bompas, E.; Borel, C.; Bouchekoua, M.; Bozec LE Moal, L.; Bruyas, A.; Calais, G.; Carpiuc, I.; Chapet, S.; Chatellier, T.; Chauffert, B.; Cheli, S.; Clatot, F.; Cojocarasu, O.; Cornelly, A.; Coutte, A.; Dalloz, P.; Darloy, F.; Delhommeau, M.; DE Raucourt, D.; Debel 2021: Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial LANCET. Oncology 22(4): 463-475
Jimeno, A.; Machiels, J.-P.; Wirth, L.; Specenier, P.; Seiwert, T.Y.; Mardjuadi, F.; Wang, X.; Kapp, A.V.; Royer-Joo, S.; Penuel, E.; McCall, B.; Pirzkall, A.; Clement, P.M. 2016: Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck Cancer 122(24): 3803-3811
Hsieh, M.-C.; Wang, C.-C.; Yang, C.-C.; Lien, C.-F.; Wang, C.-C.; Shih, Y.-C.; Yeh, S.-A.; Hwang, T.-Z. 2021: Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: a Propensity Score Matching Analysis Biology 10(10)
Mutlu, H.; Salim, D.K.ıv.; Gündüz, Şe.; Eryılmaz, M.K.; Musri, F.Y.çın.; Coşkun, H.Şe. 2017: Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard? Journal of Cancer Research and Therapeutics 13(3): 510-513
Kua, V.F.; Ismail, F.; Chee Ee Phua, V.; Aslan, N.M. 2013: Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma Asian Pacific Journal of Cancer Prevention: Apjcp 14(2): 1121-1126
Cognetti, F.; Clerico, M.; Vermorken, J.; Van Rymenant, M.; Rossi, A.; Kirkpatrick, A.; Dalesic, O.; Clavel, M. 1986: Phase Ii trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck European Journal of Cancer and Clinical Oncology 22(7): 891-892
Cognetti, F.; Dodion, P.; Clerico, M.; Vermorken, J.B.; Van Rijmenant, M.; Clavel, M.; Dalesio, O.; Kirkpatrick, A.; Rossi, A. 1984: Phase ii trial of a combination of low dose cisplatin and bolus 5 fluorouracil in recurrent and metastatic squamous cell carcinoma of the head and neck Cancer Immunology Immunotherapy 18(Suppl): S14
Gebbia, V.; Mantovani, G.; Agostara, B.; Contu, A.; Farris, A.; Colucci, G.; Cognetti, F.; Restivo, G.; Speciale, R.; Ferrero, B. 1995: Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase Ii trial Annals of Oncology: Official Journal of the European Society for Medical Oncology 6(10): 987-991